Your browser doesn't support javascript.
loading
Preclinical Comparison of the Blood-brain barrier Permeability of Osimertinib with Other EGFR TKIs.
Colclough, Nicola; Chen, Kan; Johnström, Peter; Strittmatter, Nicole; Yan, Yumei; Wrigley, Gail L; Schou, Magnus; Goodwin, Richard; Varnäs, Katarina; Adua, Sally J; Zhao, Minghui; Nguyen, Don X; Maglennon, Gareth; Barton, Peter; Atkinson, James; Zhang, Lin; Janefeldt, Annika; Wilson, Joanne; Smith, Aaron; Takano, Akihiro; Arakawa, Ryosuke; Kondrashov, Mikhail; Malmquist, Jonas; Revunov, Evgeny; Vazquez-Romero, Ana; Moein, Mohammad Mahdi; Windhorst, Albert D; Karp, Natasha A; Finlay, M Raymond V; Ward, Richard A; Yates, James W T; Smith, Paul D; Farde, Lars; Cheng, Zack; Cross, Darren A E.
Afiliação
  • Colclough N; DMPK, Early Oncology TDE, AstraZeneca, Cambridge, United Kingdom. nicola.colclough@astrazeneca.com.
  • Chen K; DMPK, Dizal Pharma, Shanghai, China.
  • Johnström P; PET Science Centre, Precision Medicine and Biosamples, R&D Oncology, AstraZeneca, Karolinska Institutet, Stockholm, Sweden.
  • Strittmatter N; Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.
  • Yan Y; Clinical Pharmacology and Safety Sciences, AstraZeneca, Cambridge, United Kingdom.
  • Wrigley GL; DMPK, Dizal Pharma, Shanghai, China.
  • Schou M; Chemistry, Early Oncology TDE, AstraZeneca, Cambridge, United Kingdom.
  • Goodwin R; PET Science Centre, Precision Medicine and Biosamples, R&D Oncology, AstraZeneca, Karolinska Institutet, Stockholm, Sweden.
  • Varnäs K; Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.
  • Adua SJ; Clinical Pharmacology and Safety Sciences, AstraZeneca, Cambridge, United Kingdom.
  • Zhao M; Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.
  • Nguyen DX; Department of Pathology and Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut.
  • Maglennon G; Department of Pathology and Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut.
  • Barton P; Department of Pathology and Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut.
  • Atkinson J; Clinical Pharmacology and Safety Sciences, AstraZeneca, Cambridge, United Kingdom.
  • Zhang L; Chemistry, Early Oncology TDE, AstraZeneca, Cambridge, United Kingdom.
  • Janefeldt A; Clinical Pharmacology and Safety Sciences, AstraZeneca, Cambridge, United Kingdom.
  • Wilson J; DMPK, Dizal Pharma, Shanghai, China.
  • Smith A; DMPK, Early Cardiovascular, Renal and Metabolism, R&D BioPharmaceuticals, AstraZeneca, Gothenburg, Sweden.
  • Takano A; DMPK, Early Oncology TDE, AstraZeneca, Cambridge, United Kingdom.
  • Arakawa R; DMPK, Early Oncology TDE, AstraZeneca, Cambridge, United Kingdom.
  • Kondrashov M; Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.
  • Malmquist J; Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.
  • Revunov E; Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.
  • Vazquez-Romero A; Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.
  • Moein MM; Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.
  • Windhorst AD; Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.
  • Karp NA; Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.
  • Finlay MRV; Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands.
  • Ward RA; Data Sciences & Quantitative Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge, United Kingdom.
  • Yates JWT; Chemistry, Early Oncology TDE, AstraZeneca, Cambridge, United Kingdom.
  • Smith PD; Chemistry, Early Oncology TDE, AstraZeneca, Cambridge, United Kingdom.
  • Farde L; DMPK, Early Oncology TDE, AstraZeneca, Cambridge, United Kingdom.
  • Cheng Z; Bioscience, Early Oncology TDE, AstraZeneca, Cambridge, United Kingdom.
  • Cross DAE; PET Science Centre, Precision Medicine and Biosamples, R&D Oncology, AstraZeneca, Karolinska Institutet, Stockholm, Sweden.
Clin Cancer Res ; 27(1): 189-201, 2021 01 01.
Article em En | MEDLINE | ID: mdl-33028591
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Acrilamidas / Neoplasias Encefálicas / Barreira Hematoencefálica / Inibidores de Proteínas Quinases / Compostos de Anilina / Neoplasias Pulmonares Tipo de estudo: Prognostic_studies Limite: Animals / Humans / Male Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Acrilamidas / Neoplasias Encefálicas / Barreira Hematoencefálica / Inibidores de Proteínas Quinases / Compostos de Anilina / Neoplasias Pulmonares Tipo de estudo: Prognostic_studies Limite: Animals / Humans / Male Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido